A STUDY TO DETECT ASSOCIATION OF BODY MASS INDEX AND HYPERBILIRUBINEMIA AS WELL AS BODY MASS INDEX AND LIVER ENZYMES AMONG PATIENTS ON FIRST LINE ANTI-TUBERCULAR DRUGS FROM RNTCP DURING THE COURSE OF ANTI-TB TREATMENT

Dr. Rupam Kumar Ta; Dr. Saugata Bhaumik; Dr. Pronoy Sen

Volume : IX, Issue : II, February - 2020

A STUDY TO DETECT ASSOCIATION OF BODY MASS INDEX AND HYPERBILIRUBINEMIA AS WELL AS BODY MASS INDEX AND LIVER ENZYMES AMONG PATIENTS ON FIRST LINE ANTI-TUBERCULAR DRUGS FROM RNTCP DURING THE COURSE OF ANTI-TB TREATMENT

Dr. Rupam Kumar Ta, Dr. Saugata Bhaumik, Dr. Pronoy Sen

Abstract :

BACKGROUND Globally, estimated 10.0 million people developed Tuberculosis in 2017. Side effects and toxicity of the first line anti-tubercular drugs were hepatotoxicity, skin rash, and joint pain. Poor nutritional status has been considered to be one of the factors contributing to a higher incidence of DIH induced by short-course chemotherapy for TB in the developing countries. Hence this study was conducted to find out the association between Body Mass Index and hyperbilirubinemia as well as Body Mass Index and liver enzymes among patients on first line anti-tubercular drugs from RNTCP during the course of Anti-TB treatment. METHODS 116 patients who were diagnosed to have Pulmonary (PTB)/ Extrapulmonary (EPTB) tuberculosis at Outpatient & In-Patients of Department of Chest Medicine, Burdwan Medical College & Hospital for eleven months after fulfilling the inclusion and exclusion criteria. Treatment was given as per guidelines by Revised National TB Control Program. RESULTS Significant association was observed between BMI<18.5 kg/m2 and hyperbilirubinemia and BMI>=18.5 and elevation in SGPT level at 2nd week of treatment. CONCLUSION Hyperbilirubinemia is a common occurrence during the course of anti-TB treatment in patients with low BMI. Most patients show tolerance to anti-TB drugs and get adjusted after transient rise in liver enzymes. Clinicians should be vigilant for occurrence of hyperbilirubinemia in this high-risk group.